Vertex Pharmaceuticals (VRTX) Stock Forecast & Price Target

Compare

6,433 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

VRTX Analyst Ratings

Moderate Buy

14 Buy

8 Hold

0 Sell

Based on 22 analysts giving stock ratings to

Vertex

Pharmaceuticals

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

VRTX Stock 12 Month Forecast

Average Price Target

$488.25

▲(19.24% Upside)

Based on 22 Wall Street analysts offering 12 month price targets for Vertex Pharmaceuticals in the last 3 months. The average price target is $488.25 with a high forecast of $624.00 and a low forecast of $401.00. The average price target represents a 19.24% change from the last price of $409.47.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"400":"$400","625":"$625","456.25":"$456.3","512.5":"$512.5","568.75":"$568.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":624,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$624.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":488.25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$488.25</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":401,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$401.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[400,456.25,512.5,568.75,625],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,425.57,440.83384615384614,456.0976923076923,471.36153846153843,486.62538461538463,501.8892307692308,517.1530769230769,532.416923076923,547.6807692307692,562.9446153846154,578.2084615384615,593.4723076923077,608.7361538461539,{"y":624,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,425.57,430.39153846153846,435.2130769230769,440.0346153846154,444.85615384615386,449.6776923076923,454.49923076923073,459.3207692307692,464.14230769230767,468.96384615384613,473.7853846153846,478.60692307692307,483.42846153846153,{"y":488.25,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,425.57,423.68,421.79,419.9,418.01,416.12,414.23,412.34,410.45,408.56,406.67,404.78,402.89,{"y":401,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":471.12,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":465.73,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 60,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 33, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":402.7,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 61,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 34, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":461.68,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 59,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 38, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":479.79,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 33, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":484.74,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":498.86,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 33, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":445.43,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 39, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":452.16,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 40, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":462.13,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 32, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":401,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":404.21,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":425.57,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$624.00

Average Price Target$488.25

Lowest Price Target$401.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

David Dai

UBS

$553→$546

Buy

33.34%

Upside

Reiterated

11/07/25

Vertex Pharmaceuticals: Strong Revenue Performance and Promising Prospects Justify Buy Rating

Naz Rahman

Maxim Group

―

Hold

―

Reiterated

11/05/25

Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (NASDAQ: VRTX), Agilon Health (NYSE: AGL) and REPRO-MED Systems (NASDAQ: KRMD)

Joon Lee

Truist Financial

―

Buy

―

Reiterated

11/04/25

Vertex Pharmaceuticals (VRTX) Receives a Buy from Truist Financial

Myles Minter

William Blair

―

Buy

―

Reiterated

11/04/25

Vertex Pharmaceuticals: Strong Buy Rating Amid Promising Growth and Strategic Expansion

Andrew Fein

H.C. Wainwright

$478

Buy

16.74%

Upside

Reiterated

11/04/25

Vertex Pharmaceuticals: Promising IgAN Market Position with Povetacicept's Superior Efficacy and Patient-Friendly AdministrationValuation and Risks. Our price target of $478 is based on an equally weighted composite of: (a) $401/share, as a 15x multiple of taxed and diluted FY25 GAAP EPS of $42 discounted back to and (b) an NPV of $556/share (discount rate 8%, terminal growth rate of 1%). Risks to our investment thesis and target price include: (1) the failure of in further combination clinical studies; (2) the failure of to achieve our peak sales revenue; and (3) product competition.

Joseph Stringer

Needham

―

Hold

―

Assigned

11/04/25

Vertex Pharmaceuticals: Hold Rating Maintained Amid Mixed Financial Signals

Paul Matteis

Stifel Nicolaus

$455→$445

Hold

8.68%

Upside

Reiterated

11/04/25

Stifel Nicolaus Remains a Hold on Vertex Pharmaceuticals (VRTX)We're reiterating our Hold rating on VRTX.

Cory Kasimov

Evercore ISI

$475

Buy

16.00%

Upside

Reiterated

11/04/25

Evercore ISI Sticks to Their Buy Rating for Vertex Pharmaceuticals (VRTX)

Terence Flynn

Morgan Stanley

$438

Hold

6.97%

Upside

Reiterated

11/04/25

Morgan Stanley Keeps Their Hold Rating on Vertex Pharmaceuticals (VRTX)Vertex Pharmaceuticals maintains an Equal-Weight rating with an unchanged PT of 438 and slight EPS revisions.

Phil Nadeau

TD Cowen

$525

Buy

28.21%

Upside

Reiterated

11/04/25

Vertex Pharmaceuticals (VRTX) Receives a Buy from TD Cowen

Gena Wang

Barclays

$408→$414

Hold

1.11%

Upside

Reiterated

11/04/25

Barclays Sticks to Their Hold Rating for Vertex Pharmaceuticals (VRTX)

Brian Abrahams

RBC Capital

$423→$415

Hold

1.35%

Upside

Reiterated

11/04/25

Vertex Pharmaceuticals price target lowered to $415 from $423 at RBC CapitalVertex Pharmaceuticals price target lowered to $415 from $423 at RBC Capital

Tazeen Ahmad

Bank of America Securities

―

Buy

―

Reiterated

11/04/25

Bank of America Securities Sticks to Its Buy Rating for Vertex Pharmaceuticals (VRTX)

Evan Seigerman

BMO Capital

$530

Buy

29.44%

Upside

Reiterated

11/03/25

Optimistic Outlook for Vertex Pharmaceuticals Driven by Strong CF Business and Promising Pipeline Developments

William Pickering

Bernstein

$471

Hold

15.03%

Upside

Reiterated

10/27/25

Bernstein Reaffirms Their Hold Rating on Vertex Pharmaceuticals (VRTX)

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

David Dai

UBS

$553→$546

Buy

33.34%

Upside

Reiterated

11/07/25

Vertex Pharmaceuticals: Strong Revenue Performance and Promising Prospects Justify Buy Rating

Naz Rahman

Maxim Group

―

Hold

―

Reiterated

11/05/25

Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (NASDAQ: VRTX), Agilon Health (NYSE: AGL) and REPRO-MED Systems (NASDAQ: KRMD)

Joon Lee

Truist Financial

―

Buy

―

Reiterated

11/04/25

Vertex Pharmaceuticals (VRTX) Receives a Buy from Truist Financial

Myles Minter

William Blair

―

Buy

―

Reiterated

11/04/25

Vertex Pharmaceuticals: Strong Buy Rating Amid Promising Growth and Strategic Expansion

Andrew Fein

H.C. Wainwright

$478

Buy

16.74%

Upside

Reiterated

11/04/25

Joseph Stringer

Needham

―

Hold

―

Assigned

11/04/25

Vertex Pharmaceuticals: Hold Rating Maintained Amid Mixed Financial Signals

Paul Matteis

Stifel Nicolaus

$455→$445

Hold

8.68%

Upside

Reiterated

11/04/25

Stifel Nicolaus Remains a Hold on Vertex Pharmaceuticals (VRTX)We're reiterating our Hold rating on VRTX.

Cory Kasimov

Evercore ISI

$475

Buy

16.00%

Upside

Reiterated

11/04/25

Evercore ISI Sticks to Their Buy Rating for Vertex Pharmaceuticals (VRTX)

Terence Flynn

Morgan Stanley

$438

Hold

6.97%

Upside

Reiterated

11/04/25

Morgan Stanley Keeps Their Hold Rating on Vertex Pharmaceuticals (VRTX)Vertex Pharmaceuticals maintains an Equal-Weight rating with an unchanged PT of 438 and slight EPS revisions.

Phil Nadeau

TD Cowen

$525

Buy

28.21%

Upside

Reiterated

11/04/25

Vertex Pharmaceuticals (VRTX) Receives a Buy from TD Cowen

Gena Wang

Barclays

$408→$414

Hold

1.11%

Upside

Reiterated

11/04/25

Barclays Sticks to Their Hold Rating for Vertex Pharmaceuticals (VRTX)

Brian Abrahams

RBC Capital

$423→$415

Hold

1.35%

Upside

Reiterated

11/04/25

Vertex Pharmaceuticals price target lowered to $415 from $423 at RBC CapitalVertex Pharmaceuticals price target lowered to $415 from $423 at RBC Capital

Tazeen Ahmad

Bank of America Securities

―

Buy

―

Reiterated

11/04/25

Bank of America Securities Sticks to Its Buy Rating for Vertex Pharmaceuticals (VRTX)

Evan Seigerman

BMO Capital

$530

Buy

29.44%

Upside

Reiterated

11/03/25

Optimistic Outlook for Vertex Pharmaceuticals Driven by Strong CF Business and Promising Pipeline Developments

William Pickering

Bernstein

$471

Hold

15.03%

Upside

Reiterated

10/27/25

Bernstein Reaffirms Their Hold Rating on Vertex Pharmaceuticals (VRTX)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Vertex Pharmaceuticals

1 Month

xxx

Success Rate

25/32 ratings generated profit

Average Return

+3.84%

reiterated a xxx

rating 6 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 78.13% of your transactions generating a profit, with an average return of +3.84% per trade.

3 Months

xxx

Success Rate

20/28 ratings generated profit

Average Return

+6.84%

reiterated a xxx

rating 28 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 71.43% of your transactions generating a profit, with an average return of +6.84% per trade.

1 Year

Cory KasimovEvercore ISI

Success Rate

24/32 ratings generated profit

Average Return

+17.29%

reiterated a buy rating 6 days ago

Copying Cory Kasimov's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +17.29% per trade.

2 Years

xxx

Success Rate

27/31 ratings generated profit

Average Return

+25.45%

reiterated a xxx

rating 6 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 87.10% of your transactions generating a profit, with an average return of +25.45% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

VRTX Analyst Recommendation Trends

Rating

Jul 25

Aug 25

Sep 25

Oct 25

Nov 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, VRTX has received 32 Buy Ratings, 11 Hold Ratings, and 0 Sell Ratings. VRTX average Analyst price target in the past 3 months is 488.25.

Each month's total comprises the sum of three months' worth of ratings.

VRTX Financial Forecast

VRTX Earnings Forecast

Next quarter’s earnings estimate for VRTX is $5.12 with a range of $4.46 to $5.78. The previous quarter’s EPS was $4.80. VRTX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year VRTX has Preformed in-line its overall industry.

VRTX Sales Forecast

Next quarter’s sales forecast for VRTX is $3.19B with a range of $3.10B to $3.35B. The previous quarter’s sales results were $3.12B. VRTX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year VRTX has Preformed in-line its overall industry.

VRTX Stock Forecast FAQ

What is VRTX’s average 12-month price target, according to analysts?

Based on analyst ratings, Vertex Pharmaceuticals’s 12-month average price target is 488.25.

What is VRTX’s upside potential, based on the analysts’ average price target?

Vertex Pharmaceuticals has 19.24% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is VRTX a Buy, Sell or Hold?

Vertex Pharmaceuticals has a consensus rating of Moderate Buy which is based on 14 buy ratings, 8 hold ratings and 0 sell ratings.

What is Vertex Pharmaceuticals’s price target?

The average price target for Vertex Pharmaceuticals is 488.25. This is based on 22 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $624.00 ,the lowest forecast is $401.00. The average price target represents 19.24% Increase from the current price of $409.47.

What do analysts say about Vertex Pharmaceuticals?

Vertex Pharmaceuticals’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 22 Wall Streets Analysts.

How can I buy shares of VRTX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Vertex Pharmaceuticals (VRTX) Stock Forecast & Price Target

VRTX Analyst Ratings

VRTX Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Vertex Pharmaceuticals

VRTX Analyst Recommendation Trends

VRTX Financial Forecast

VRTX Earnings Forecast

VRTX Sales Forecast

VRTX Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts